This study will be conducted in 2 parts. The phase 1b part will be an international, phase 1b, open-label, dose-escalation assessment of radium-223 dichloride administered with bortezomib and dexamethasone in subjects with relapsed multiple myeloma. The primary endpoint is to determine the optimal dose of radium-223 dichloride in combination with ...

The key purpose of the main part of the study is to assess efficacy and safety of anetumab ravtansine as monotherapy or combination therapy for mesothelin expressing advanced solid tumors. The main purpose of the safety lead-in (dose-finding) part of the study is to determine the safety and tolerability of ...

Study for Pediatric ADHD Learning that your 4 to 12 year old child has attention-deficit/hyperactivity disorder (ADHD) is challenging. It may leave you wondering what options are available for your child and whether they will be safe for your child at such a young age. New clinical research studies will ...

The INSTRIDE Studies are looking to see how well an investigational insulin works to control blood sugar levels. The investigational insulin has been designed to be as similar as possible to insulin glargine (Lantus®), which has helped many people with diabetes worldwide. The investigational insulin could be a more affordable ...

The ATLAS clinical research study is being conducted to assess the safety and efficacy of an investigational medication plus gonadotropin releasing hormone agonist (GnRHa) in subjects with high-risk, localized or locally advanced prostate cancer receiving treatment with primary radiation therapy. The study will enroll 1,500 patients with high-risk, localized or ...

This Phase III study is designed as a randomized, double-blinded, placebo-controlled study for subjects with evidence of early AD. The study will evaluate safety and tolerability, efficacy as measured by CDR-SB, and will determine if the combination therapy ALZT-OP1 will slow down, arrests, or reverse cognitive and functional decline in ...

This Phase III study is designed as a randomized, double-blinded, placebo-controlled study for subjects with evidence of early AD. The study will evaluate safety and tolerability, efficacy as measured by CDR-SB, and will determine if the combination therapy ALZT-OP1 will slow down, arrests, or reverse cognitive and functional decline in ...